Adapt Pharma Limited

Company overview. Adapt Pharma Limited is an Irish specialty pharmaceutical company. Its corporate headquarters was in Dublin (45 Fitzwilliam Square), with U.S. operations headquartered in Radnor, Pennsylvania. It was founded in the mid-2010s by serial biotech investor Seamus Mulligan and was privately held — never publicly traded. In August 2018 Emergent BioSolutions Inc. (NYSE: EBS) agreed to acquire Adapt for up to $735 million ($635 million upfront plus $100 million in sales milestones), and the deal closed in October 2018, bringing over roughly 50 employees across the U.S., Canada, and Ireland. No independent revenue figure for Adapt is published; Emergent projected $200–220 million in 2019 incremental revenue from the acquisition.

Products / operations. Adapt was an operating specialty pharma company, not an NPE. Its flagship — and, at the time of sale, only marketed — product was NARCAN® (naloxone hydrochloride) Nasal Spray, the first FDA-approved needle-free intranasal formulation for emergency treatment of known or suspected opioid overdose, approved November 2015 (NDA No. 208411) and launched in early 2016; a 2 mg version followed and Health Canada approved the product in 2016. It also had a small pipeline of opioid-overdose treatment and delivery assets. It did not manufacture the device itself; the spray device was supplied by Aptar.

Patent-litigation posture. Adapt was predominantly a plaintiff, consistent with the case data (3 plaintiff cases, 1 defendant). It asserted Orange Book-listed naloxone nasal-spray patents — largely exclusively licensed from Opiant Pharmaceuticals (formerly Lightlake Therapeutics) — against generic ANDA filers. All district court cases were filed in the District of New Jersey, its home forum, not a plaintiff-friendly venue like the Eastern District of Texas. Its single defendant-side appearance is a PTAB inter partes review.

Notable cases/context. Adapt Pharma Operations Limited v. Teva Pharmaceuticals USA, Inc. (D.N.J., filed 2016 and 2018) and Adapt Pharma Operations Limited v. Perrigo UK FINCO Limited Partnership (D.N.J., filed 2018) were Hatch-Waxman suits over generic naloxone nasal spray. Following a 2020 bench trial, the district court held the asserted claims obvious; the Federal Circuit affirmed in Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc., 25 F.4th 1354 (Fed. Cir. 2022), with Judge Newman dissenting. Separately, Nalox-1 Pharmaceuticals, LLC petitioned for IPRs of the NARCAN patents (2019), naming Adapt Pharma Limited and Opiant as patent owners; the PTAB declined to institute several petitions and upheld three patents in 2020.